ウィスコンシンにおける多発性骨髄腫の臨床試験
ウィスコンシン内の拠点で、多発性骨髄腫に関する28件の研究が参加者を募集しています。
ウィスコンシン内の都市
公式研究テキスト（英語）
Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)
- Mayo Clinic Health System-Eau Claire Clinic, Eau Claire
- Mayo Clinic Health System-Franciscan Healthcare, La Crosse
被験者募集中
18歳以上 · 全性別 · 2026/10/01更新 · NCT06630104A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Madison
- Research Site, Milwaukee
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/29更新 · NCT07391657A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- University of Wisconsin Carbone Cancer Center, Madison
- Medical College of Wisconsin, Milwaukee
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT04973605A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- Medical College Of Wisconsin, Milwaukee
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07258511A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Froedtert Memorial, Milwaukee
被験者募集中第4相
18歳以上 · 全性別 · 2026/09/25更新 · NCT05201781A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
- The Medical College of Wisconsin, Milwaukee
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/23更新 · NCT07116616TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Aurora Cancer Care - Burlington, Burlington
- Aurora Health Care - Germantown Health Center, Germantown
- Aurora Cancer Care - Grafton, Grafton
- 他13件
被験者募集中第2相
12歳以上 · 全性別 · 2026/09/22更新 · NCT02693535Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Medical College of Wisconsin, Milwaukee
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/21更新 · NCT07648264A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- Medical College of Wisconsin, Milwaukee
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/15更新 · NCT06615479Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/14更新 · NCT06297226Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
- University of Wisconsin, Madison
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/31更新 · NCT07479979A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
- Research Site, Milwaukee
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/27更新 · NCT07681596MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center-University Hospital, Madison
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/24更新 · NCT06152575Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- ThedaCare Regional Cancer Center, Appleton
- Ascension Northeast Wisconsin-Saint Elizabeth Cancer Center-Appleton, Appleton
- Ascension Southeast Wisconsin Hospital-Elmbrook Campus-Brookfield, Brookfield
- 他47件
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/19更新 · NCT04566328Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
- Gundersen Lutheran, La Crosse
被験者募集中第3相
18歳〜79歳 · 全性別 · 2026/08/17更新 · NCT07285239AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Milwaukee
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/17更新 · NCT05850234Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma
- Froedtert & the Medical College of Wisconsin, Milwaukee
被験者募集中第1相
18歳〜80歳 · 全性別 · 2026/08/10更新 · NCT05976555A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- University of Wisconsin - Carbone Cancer Center, Madison
- MCW-Clinical Cancer Center at Froedtert Hospital Campus, Milwaukee
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/06更新 · NCT07284758Moving Forward With Myeloma: A Lifestyle Intervention for Individuals With Multiple Myeloma
- Medical College of Wisconsin, Milwaukee
被験者募集中
18歳以上 · 全性別 · 2026/07/22更新 · NCT07236502Integrated Cancer Repository for Cancer Research
- Bellin Memorial Hospital, Green Bay
被験者募集中観察研究健康なボランティア歓迎
19歳〜110歳 · 全性別 · 2026/06/29更新 · NCT02012699Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Langlade Hospital and Cancer Center, Antigo
- ThedaCare Regional Cancer Center, Appleton
- Duluth Clinic Ashland, Ashland
- 他22件
被験者募集中第3相
全年齢 · 全性別 · 2026/06/10更新 · NCT05561387Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- St Vincent HSHS (Green Bay Oncology), Green Bay
- University of Wisconsin Hospital and Clinics, Madison
- Froedtert Memorial Lutheran Hospital, Milwaukee
被験者募集中第3相
18歳以上 · 全性別 · 2026/06/04更新 · NCT05243797Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
- University of Wisconsin Clinical Science Center, Madison
- Medical College of Wisconsin, Milwaukee
被験者募集中第2相
19歳以上 · 全性別 · 2026/06/04更新 · NCT06974786Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
- Froedtert Hospital & the Medical College of Wisconsin, Milwaukee
被験者募集中第1相
18歳以上 · 全性別 · 2026/04/01更新 · NCT05862012Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency
- Froedtert Hospital & the Medical College of Wisconsin, Milwaukee
被験者募集中第2相
18歳以上 · 全性別 · 2026/01/28更新 · NCT04240054Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma
- Froedtert & the Medical College of Wisconsin, Milwaukee
被験者募集中第1相
18歳以上 · 全性別 · 2026/01/05更新 · NCT07093554Long-term Follow-up Study of Patients Receiving CAR-T Cells
- Froedtert Hospital & Medical College of Wisconsin, Milwaukee
被験者募集中観察研究
18歳〜80歳 · 全性別 · 2025/11/10更新 · NCT03375619CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
- Froedtert and the Medical College of Wisconsin, Milwaukee
被験者募集中第1相
18歳以上 · 全性別 · 2025/09/25更新 · NCT05722418ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。